HC Wainwright Reiterates “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Tuesday,Benzinga reports. They presently have a $9.00 price target on the stock.

A number of other equities research analysts also recently weighed in on the company. Maxim Group decreased their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. D. Boral Capital cut their price target on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Tuesday.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN LCTX opened at $0.64 on Tuesday. Lineage Cell Therapeutics has a fifty-two week low of $0.48 and a fifty-two week high of $1.61. The stock has a market cap of $141.29 million, a price-to-earnings ratio of -5.34 and a beta of 1.21.

Institutional Trading of Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in shares of Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock worth $35,000 after acquiring an additional 18,053 shares during the period. HighTower Advisors LLC grew its position in Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock valued at $29,000 after acquiring an additional 19,100 shares during the last quarter. Fort Sheridan Advisors LLC boosted its stake in shares of Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock valued at $28,000 after purchasing an additional 23,000 shares in the last quarter. Defender Capital LLC. grew its holdings in shares of Lineage Cell Therapeutics by 0.6% during the 3rd quarter. Defender Capital LLC. now owns 5,002,198 shares of the company’s stock valued at $4,528,000 after purchasing an additional 29,223 shares during the last quarter. Finally, MAI Capital Management increased its position in Lineage Cell Therapeutics by 2.2% during the 3rd quarter. MAI Capital Management now owns 1,674,679 shares of the company’s stock worth $1,516,000 after purchasing an additional 35,907 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.